E913 is a CCR5 antagonist that competes with the binding of antibodies to CCR5 which recognize the C-terminal half of the second extracellular loop (ECL2B) of CCR5 . E913 can specifically block the binding of macrophage inflammatory protein-1alpha (MIP-1alpha) to CCR5 ( IC 50 = 0.002 μM) and MIP-1alpha-elicited cellular Ca 2+ mobilization ( IC 50 = 0.02 μM). E913 inhibits the replication of laboratory and primary R5 HIV-1 strains as well as various multidrug-resistant monocyte/macrophage tropic (R5) HIV-1 ( IC 50 = 0.03-0.06 μM). E913 can be used for the research of infection , such as HIV-1 infection.
Products | Products > Disease Areas > Infection | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > CCR | Products > Signaling Pathways > HIV
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.